Insider Selling: Tempus AI (NASDAQ:TEM) Director Sells $16,058.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) Director David Epstein sold 370 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $43.40, for a total transaction of $16,058.00. Following the transaction, the director owned 31,094 shares in the company, valued at $1,349,479.60. The trade was a 1.18% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Price Performance

Shares of TEM opened at $52.05 on Friday. The firm has a market capitalization of $9.35 billion, a PE ratio of -36.15 and a beta of 3.58. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI, Inc. has a 1-year low of $40.77 and a 1-year high of $104.32. The company’s fifty day moving average price is $51.33 and its 200-day moving average price is $51.95.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million during the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the business posted ($0.22) EPS. The firm’s quarterly revenue was up 21.6% on a year-over-year basis. On average, equities research analysts predict that Tempus AI, Inc. will post -1.38 EPS for the current year.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. GC Wealth Management RIA LLC acquired a new position in Tempus AI in the fourth quarter valued at approximately $399,267,000. Voloridge Investment Management LLC boosted its position in Tempus AI by 183.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after purchasing an additional 1,039,176 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Tempus AI during the 2nd quarter worth approximately $54,020,000. Amova Asset Management Americas Inc. increased its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after purchasing an additional 821,490 shares in the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Tempus AI by 23.4% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after purchasing an additional 821,490 shares in the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms recently commented on TEM. TD Cowen reaffirmed a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. Lake Street Capital lowered Tempus AI to a “hold” rating in a research report on Monday, July 20th. Needham & Company LLC reiterated a “buy” rating and issued a $75.00 price target on shares of Tempus AI in a report on Friday, July 31st. Stifel Nicolaus reduced their price target on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a research report on Monday, August 3rd. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Nine equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Hold” and an average price target of $64.92.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.